Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
| Revenue (TTM) | $96.36B |
| Gross Profit (TTM) | $65.56B |
| EBITDA | $34.33B |
| Operating Margin | 27.40% |
| Return on Equity | 26.40% |
| Return on Assets | 8.42% |
| Revenue/Share (TTM) | $40.02 |
| Book Value | $33.73 |
| Price-to-Book | 7.80 |
| Price-to-Sales (TTM) | 6.58 |
| EV/Revenue | 6.91 |
| EV/EBITDA | 19.76 |
| Quarterly Earnings Growth (YoY) | -52.90% |
| Quarterly Revenue Growth (YoY) | 9.90% |
| Shares Outstanding | $2.41B |
| Float | $2.40B |
| % Insiders | 0.05% |
| % Institutions | 76.82% |
Volatility is currently expanding
A sharp sector rotation has knocked down some of the market's steadiest names, and Jim Cramer told CNBC viewers this week that the dislocations are exactly the kind of setup patient investors should welcome.
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
For today's Big 3, Dan Deming turns to three stocks he sees fitting the theme of a broadening market as investors rotate out of AI and offer strength for other sectors. He explains why he sees opportunities in UnitedHealth (UNH), Coca-Cola (KO), and Johnson & Johnson (JNJ).
Fundstrat's Tom Lee returned to CNBC's Morning Call Sheet on Thursday, July 9, alongside JonesTrading's Mike O'Rourke and Vital Knowledge's Adam Crisafulli, to discuss a market that is simultaneously celebrating the AI build-out while rotating into value and defensive names.
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform.
Johnson & Johnson has delivered a 43% total return over 9 months, but I maintain a 'Hold' rating due to overvaluation concerns. JNJ's Q1 '26 showed 10% sales growth, but adjusted operational growth was only 5.3% and adjusted EPS declined 2.5% year-over-year. Management targets double-digit growth by the decade's end, yet consensus forecasts only ~6% EPS CAGR, and valuation multiples require aggressive growth assumptions.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
JNJ's Q2 MedTech results will test whether cardiovascular, surgery and vision strength can offset ongoing China VBP headwinds and sustain growth.
Johnson & Johnson (NYSE:JNJ) will release its second quarter earnings report before the opening bell on Wednesday, July 15.
